(Q33237366)

English

Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 July 2017

0 references

1 reference

Europe PubMed Central

Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials (English)

1 reference

Europe PubMed Central

24 July 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Dahlöf CG

1

1 reference

Europe PubMed Central

24 July 2017

Pascual J

2

1 reference

Europe PubMed Central

24 July 2017

Dodick DW

3

1 reference

Europe PubMed Central

24 July 2017

Dowson AJ

4

1 reference

Europe PubMed Central

24 July 2017

language of work or name

0 references

publication date

1 April 2006

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

26

1 reference

Europe PubMed Central

24 July 2017

4

1 reference

Europe PubMed Central

24 July 2017

400-408

1 reference

Europe PubMed Central

24 July 2017

Burden of migraine: societal costs and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Acute and prophylactic management of migraine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Advances in pharmacological treatment of migraine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Migraine--current understanding and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Determinants of patient satisfaction with migraine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Treatment preferences and the selection of acute migraine medications: results from a population-based survey

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Establishing a standard of speed for assessing the efficacy of the serotonin(1B/1D) agonists (triptans).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

The statistical basis of meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Acute migraine treatment outcome measures: a clinician's view

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2005.01080.X

21 January 2018

Identifiers

10.1111/J.1468-2982.2005.01080.X

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33237366&oldid=1623584156"